Compare AstraZeneca plc (AZN) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Monster Beverage Corp — how do they compare? AstraZeneca plc trades at $156 (market cap $245.16B), while Monster Beverage Corp trades at $46.75 (market cap $90.08B). The key difference: AstraZeneca plc is far larger — about 2.7× Monster Beverage Corp's market cap, and AstraZeneca plc pays a 2.02% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| AZN | MNST | |
|---|---|---|
Market Cap | $245.16B | $90.08B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $49.97 |
52-Week Low | $147.06 | $30.86 |
Enterprise Value | $272.43B | $88.37B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.24, down 0.95% on the day, amid bearish technical signals and merger speculation. The company shows strong fundamentals with revenue growth from $44.4B in 2022 to $58.7B in 2025 and net income margin improving to 17.4%. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing selling pressure and legal investigations creating near-term uncertainty.
AZN presents a mixed outlook with strong pharmaceutical fundamentals offset by technical weakness and merger-related volatility. The investment case hinges on continued earnings growth and strategic execution, while risks include integration challenges from potential M&A and ongoing legal scrutiny. Wall Street remains predominantly bullish despite recent price pressure.
Monster Beverage (MNST) trades at $46.68, up 2.55% with mixed technical signals showing bearish moving averages but bullish oscillators. The company demonstrates strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, maintaining robust profit margins above 23%. Recent Q2 2026 earnings missed expectations despite record quarterly sales, while analyst consensus remains positive with a $51.14 price target.
MNST presents growth potential through international expansion and strong brand positioning, though elevated valuation ratios (P/E 42.57) and competitive pressures warrant caution. The stock split effective August 11, 2026, enhances accessibility while recent earnings volatility suggests monitoring execution consistency. Risk-reward appears balanced given current technical weakness against solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
